Bruno Mendes Roatt

List of Publications by Citations

99 papers	1,580 citations	24 h-index	32 g-index
100 ext. papers	1,988 ext. citations	3.6 avg, IF	4.19 L-index

#	Paper	IF	Citations
99	Prevalence and factors associated with Leishmania infantum infection of dogs from an urban area of Brazil as identified by molecular methods. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1291	4.8	98
98	Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. *Vaccine*, **2007**, 25, 7674-86	4.1	55
97	Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. *Frontiers in Immunology*, **2014**, 5, 272	8.4	52
96	Evaluation of change in canine diagnosis protocol adopted by the visceral leishmaniasis control program in Brazil and a new proposal for diagnosis. *PLoS ONE*, **2014**, 9, e91009	3.7	47
95	Parasite burden in hamsters infected with two different strains of leishmania (Leishmania) infantum: "Leishman Donovan units" versus real-time PCR. *PLoS ONE*, **2012**, 7, e47907	3.7	45
94	Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. *Scientific Reports*, **2017**, 7, 40804	4.9	41
93	A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. *Vaccine*, **2008**, 26, 623-38	4.1	41
92	Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation. *PLoS ONE*, **2012**, 7, e49780	3.7	37
91	Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. *Revista Da Sociedade Brasileira De Medicina Tropical*, **2016**, 49, 398-407	1.5	37
90	Molecular diagnosis of canine visceral leishmaniasis: a comparative study of three methods using skin and spleen from dogs with natural Leishmania infantum infection. *Veterinary Parasitology*, **2013**, 197, 498-503	2.8	35
89	Recent advances and new strategies on leishmaniasis treatment. *Applied Microbiology and Biotechnology*, **2020**, 104, 8965-8977	5.7	34
88	Immunological profile of resistance and susceptibility in naturally infected dogs by Leishmania infantum. *Veterinary Parasitology*, **2014**, 205, 472-82	2.8	33
87	An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis. *Veterinary Parasitology*, **2016**, 217, 81-8	2.8	31
86	Peptide Vaccines for Leishmaniasis. *Frontiers in Immunology*, **2018**, 9, 1043	8.4	31
85	Clinical forms of canine visceral Leishmaniasis in naturally Leishmania infantum-infected dogs and related myelogram and hemogram changes. *PLoS ONE*, **2013**, 8, e82947	3.7	31
84	Poloxamer 407 (Pluronic( ) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. *Experimental Parasitology*, **2016**, 169, 34-42	2.1	30
83	A recombinant chimeric protein composed of human and mice-specific CD4 and CD8 T-cell epitopes protects against visceral leishmaniasis. *Parasite Immunology*, **2017**, 39, e12359	2.2	30

82	Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis. *Parasite Immunology*, **2015**, 37, 646-56	2.2	30
81	Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system. *Parasitology International*, **2016**, 65, 728-736	2.1	29
80	Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis. *Cellular Immunology*, **2018**, 323, 59-69	4.4	27
79	A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. *Frontiers in Immunology*, **2017**, 8, 217	8.4	26
78	Clinical, hematological and biochemical alterations in hamster (Mesocricetus auratus) experimentally infected with Leishmania infantum through different routes of inoculation. *Parasites and Vectors*, **2016**, 9, 181	4	26
77	Canine visceral leishmaniasis: incidence and risk factors for infection in a cohort study in Brazil. *Veterinary Parasitology*, **2013**, 197, 411-7	2.8	25
76	A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis. *Parasitology Research*, **2016**, 115, 1649-58	2.4	24
75	Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. *Experimental Parasitology*, **2018**, 186, 24-35	2.1	23
74	The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs. *Memorias Do Instituto Oswaldo Cruz*, **2014**, 109, 1005-13	2.6	22
73	A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection. *Molecular Immunology*, **2016**, 76, 70-9	4.3	22
72	Leishmania infantum mimotopes and a phage-ELISA assay as tools for a sensitive and specific serodiagnosis of human visceral leishmaniasis. *Diagnostic Microbiology and Infectious Disease*, **2017**, 87, 219-225	2.9	21
71	An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. *Parasitology Research*, **2016**, 115, 4083-4095	2.4	21
70	In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic F127-based polymeric micelle system against Leishmania amazonensis infection. *Biomedicine and Pharmacotherapy*, **2019**, 109, 779-787	7.5	21
69	Vaccination with a CD4 and CD8 T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. *Translational Research*, **2018**, 200, 18-34	11	20
68	LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4+ and CD8+) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis. *Parasites and Vectors*, **2014**, 7, 61	4	19
67	A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis. *Acta Tropica*, **2016**, 154, 73-81	3.2	18
66	An ELISA immunoassay employing a conserved Leishmania hypothetical protein for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans. *Cellular Immunology*, **2017**, 318, 42-48	4.4	17
65	A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis. *Cytokine*, **2018**, 111, 131-139	4	17

64	Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis. *Veterinary Parasitology*, **2013**, 198, 371-81	2.8	17
63	A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection. *Cellular Immunology*, **2017**, 313, 32-42	4.4	16
62	New serological tools for improved diagnosis of human tegumentary leishmaniasis. *Journal of Immunological Methods*, **2016**, 434, 39-45	2.5	16
61	Canine visceral leishmaniasis biomarkers and their employment in vaccines. *Veterinary Parasitology*, **2019**, 271, 87-97	2.8	15
60	Shotgun proteomics to unravel the complexity of the Leishmania infantum exoproteome and the relative abundance of its constituents. *Molecular and Biochemical Parasitology*, **2014**, 195, 43-53	1.9	15
59	A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection. *Parasitology International*, **2019**, 68, 63-72	2.1	15
58	Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients. *Parasitology Research*, **2017**, 116, 1197-1206	2.4	14
57	Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection. *Parasites and Vectors*, **2017**, 10, 617	4	14
56	Analysis using canine peripheral blood for establishing in vitro conditions for monocyte differentiation into macrophages for Leishmania chagasi infection and T-cell subset purification. *Veterinary Parasitology*, **2013**, 198, 62-71	2.8	14
55	A clioquinol-containing Pluronic F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model. *Parasite*, **2020**, 27, 29	3	13
54	A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against infection. *Npj Vaccines*, **2020**, 5, 75	9.5	13
53	Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species. *Acta Tropica*, **2016**, 158, 220-230	3.2	12
52	Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	12
51	A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection. *Immunobiology*, **2017**, 222, 251-260	3.4	12
50	Recent advances and new strategies in Leishmaniasis diagnosis. *Applied Microbiology and Biotechnology*, **2020**, 104, 8105-8116	5.7	12
49	Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice. *Acta Tropica*, **2017**, 171, 8-16	3.2	11
48	Evaluation of a prototype flow cytometry test for serodiagnosis of canine visceral leishmaniasis. *Vaccine Journal*, **2013**, 20, 1792-8		11
47	Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. *Parasites and Vectors*, **2016**, 9, 472	4	11

46	Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection. *Molecular Immunology*, **2019**, 106, 108-118	4.3	11
45	Impact of dose and surface features on plasmatic and liver concentrations of biodegradable polymeric nanocapsules. *European Journal of Pharmaceutical Sciences*, **2017**, 105, 19-32	5.1	10
44	Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis. *Molecular Immunology*, **2017**, 91, 272-281	4.3	10
43	Synthetic Peptides Elicit Strong Cellular Immunity in Visceral Leishmaniasis Natural Reservoir and Contribute to Long-Lasting Polyfunctional T-Cells in BALB/c Mice. *Vaccines*, **2019**, 7,	5.3	10
42	Histological study of cell migration in the dermis of hamsters after immunisation with two different vaccines against visceral leishmaniasis. *Veterinary Immunology and Immunopathology*, **2009**, 128, 418-24	2	10
41	High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection. *Parasitology*, **2019**, 146, 322-332	2.7	10
40	Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T Cells That Trigger Protection against Experimental Visceral Leishmaniasis. *Vaccines*, **2020**, 8,	5.3	9
39	Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope. *Journal of Immunological Methods*, **2019**, 474, 112641	2.5	9
38	Dogs infected with the blood trypomastigote form of Trypanosoma cruzi display an increase expression of cytokines and chemokines plus an intense cardiac parasitism during acute infection. *Molecular Immunology*, **2014**, 58, 92-7	4.3	9
37	Cellular immunophenotypic profile in the splenic compartment during canine visceral leishmaniasis. *Veterinary Immunology and Immunopathology*, **2014**, 157, 190-6	2	9
36	Dogs immunized with LBSap vaccine displayed high levels of IL-12 and IL-10 cytokines and CCL4, CCL5 and CXCL8 chemokines in the dermis. *Molecular Immunology*, **2013**, 56, 540-8	4.3	9
35	Immunization with the HisAK70 DNA Vaccine Induces Resistance against Infection in BALB/c Mice. *Vaccines*, **2019**, 7,	5.3	9
34	Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis. *Vaccines*, **2020**, 8,	5.3	8
33	Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge. *PLoS ONE*, **2016**, 11, e0161169	3.7	8
32	Performance of Leishmania braziliensis enolase protein for the serodiagnosis of canine and human visceral leishmaniosis. *Veterinary Parasitology*, **2017**, 238, 77-81	2.8	7
31	Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis. *Cytokine*, **2020**, 129, 155031	4	7
30	Neutrophil properties in healthy and Leishmania infantum-naturally infected dogs. *Scientific Reports*, **2019**, 9, 6247	4.9	6
29	Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans. *Cellular Immunology*, **2018**, 331, 67-77	4.4	6

28	Association between mast cells, tissue remodelation and parasite burden in the skin of dogs with visceral leishmaniasis. *Veterinary Parasitology*, **2017**, 243, 260-266	2.8	5
27	Effect of the preservative and temperature conditions on the stability of Leishmania infantum promastigotes antigens applied in a flow cytometry diagnostic method for canine visceral leishmaniasis. *Diagnostic Microbiology and Infectious Disease*, **2013**, 76, 470-6	2.9	5
26	Effect on cellular recruitment and the innate immune response by combining saponin, monophosphoryl lipid-A and Incomplete Freund's Adjuvant with Leishmania (Viannia) braziliensis antigens for a vaccine formulation. *Vaccine*, **2019**, 37, 7269-7279	4.1	4
25	Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis. *Molecular Immunology*, **2020**, 124, 161-171	4.3	4
24	Prednisolone and cyclosporine A: effects on an experimental model of ancylostomiasis. *Experimental Parasitology*, **2013**, 133, 80-8	2.1	4
23	Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis. *Parasite Immunology*, **2020**, 42, e12784	2.2	4
22	A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. *Vaccine*, **2021**, 39, 2755-2763	4.1	4
21	Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis. *Parasitology Research*, **2021** , 120, 321-335	2.4	4
20	Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis. *Experimental Parasitology*, **2021**, 221, 108059	2.1	4
19	Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis. *Parasite Immunology*, **2016**, 38, 108-17	2.2	3
18	Comparative analysis of real-time PCR assays in the detection of canine visceral leishmaniasis. *Parasitology Research*, **2018**, 117, 3341-3346	2.4	3
17	Liver infusion tryptose (LIT): the best choice for growth, viability, and infectivity of Leishmania infantum parasites. *Parasitology Research*, **2020**, 119, 4185-4195	2.4	3
16	Establishment of monoclonal antibodies to evaluate the cellular immunity in a hamster model of L infantum infection. *Parasite Immunology*, **2021**, 43, e12823	2.2	3
15	In vitro and in vivo antileishmanial activity of □acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis. *Parasite*, **2021**, 28, 38	3	3
14	Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells. *Parasitology Research*, **2020**, 119, 2609-2622	2.4	2
13	A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis. *Cellular Immunology*, **2020**, 356, 104194	4.4	2
12	Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. *Medical Microbiology and Immunology*, **2021**, 210, 133-147	4	2
11	Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.. *Current Research in Immunology*, **2021**, 2, 194-201	1	1

List of Publications

10	Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.. *Parasitology*, **2022**, 149, 371-379	2.7	1
9	Phase I and II Clinical Trial Comparing the LBSap, Leishmune, and Leish-Tec Vaccines against Canine Visceral Leishmaniasis. *Vaccines*, **2020**, 8,	5.3	1
8	Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection. *Microbial Pathogenesis*, **2021**, 151, 104745	3.8	1
7	IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis. *Molecular Immunology*, **2021**, 137, 20-27	4.3	1
6	Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.. *Experimental Parasitology*, **2021**, 233, 108205	2.1	0
5	Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. *Molecular Immunology*, **2021**, 141, 70-78	4.3	0
4	Recombinant guanosine-5∀triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.. *Cytokine*, **2022**, 153, 155865	4	0
3	A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantum.. *Acta Tropica*, **2022**, 230, 106412	3.2	0
2	Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.. *Parasite Immunology*, **2022**, e12921	2.2	0
1	Down regulation of IL-10 and TGF-␣ mRNA expression associated with reduced inflammatory process correlates with control of parasitism in the liver after treatingL. infantuminfected dogs with the LBMPL vaccine therapy.. *Cytokine*, **2022**, 153, 155838	4	